LOWELL, Mass., Jan. 8, 2018 /PRNewswire/ -- Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders through an advanced precision delivery platform announced that it has entered into a research collaboration agreement to improve intrathecal, or intraspinal, delivery of therapies for rare and orphan neurological conditions.
Alcyone's proprietary Pulsar™ advanced precision CNS delivery platform utilizes the cerebrospinal fluid dynamics to precision deliver and optimally biodistribute therapeutics to targets of interest in the CNS. The platform includes an intelligent intrathecal infusion system that can be coupled to a specialized multi-port spinal needle or a specialized multi-port implantable catheter designed for patients with complex spine conditions. The Pulsar system eliminates any inconsistencies and variability that may arise with manual bolus injections into the intrathecal space. The platform is being designed to be easily deployed in the clinical setting without the need for change in clinical workflow and to allow for ease of use with custom therapy-specific infusion algorithms for treating several rare and orphan CNS diseases.
"Precision delivery of disease modifying therapies to the CNS via intrathecal delivery is challenging. It is even more challenging when the patients have deformed spinal conditions or have procedures done to stabilize the spinal conditions," said PJ Anand, Alcyone's chief executive officer. "Our Pulsar platform is a powerful tool based on understanding of the cerebrospinal fluid dynamics, and we are excited about this third party validation and also this opportunity to contribute toward better intrathecal therapy of patients with debilitating CNS conditions."
Alcyone Lifesciences, Inc.Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held company focused on transforming disease modifying therapies for rare, orphan and debilitating neurological disorders through an advanced precision delivery platform. For more information, please visit www.alcyonels.com
ContactAlcyone Life Sciences, Inc.PJ AnandChief Executive [email protected]
Advertisement
Alcyone's proprietary Pulsar™ advanced precision CNS delivery platform utilizes the cerebrospinal fluid dynamics to precision deliver and optimally biodistribute therapeutics to targets of interest in the CNS. The platform includes an intelligent intrathecal infusion system that can be coupled to a specialized multi-port spinal needle or a specialized multi-port implantable catheter designed for patients with complex spine conditions. The Pulsar system eliminates any inconsistencies and variability that may arise with manual bolus injections into the intrathecal space. The platform is being designed to be easily deployed in the clinical setting without the need for change in clinical workflow and to allow for ease of use with custom therapy-specific infusion algorithms for treating several rare and orphan CNS diseases.
Advertisement
"Precision delivery of disease modifying therapies to the CNS via intrathecal delivery is challenging. It is even more challenging when the patients have deformed spinal conditions or have procedures done to stabilize the spinal conditions," said PJ Anand, Alcyone's chief executive officer. "Our Pulsar platform is a powerful tool based on understanding of the cerebrospinal fluid dynamics, and we are excited about this third party validation and also this opportunity to contribute toward better intrathecal therapy of patients with debilitating CNS conditions."
Alcyone Lifesciences, Inc.Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held company focused on transforming disease modifying therapies for rare, orphan and debilitating neurological disorders through an advanced precision delivery platform. For more information, please visit www.alcyonels.com
ContactAlcyone Life Sciences, Inc.PJ AnandChief Executive [email protected]
View original content:http://www.prnewswire.com/news-releases/alcyone-lifesciences-announces-research-collaboration-with-a-leading-biopharmaceutical-company-to-improve-intrathecal-delivery-of-therapies-for-rare-and-orphan-neurological-conditions-300578768.html
SOURCE Alcyone Lifesciences, Inc.
